|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
|
ES2320438T7
(es)
|
2002-04-09 |
2013-02-14 |
Flamel Technologies |
Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s)
|
|
MXPA05007381A
(es)
|
2003-01-13 |
2006-02-10 |
Dynogen Pharmaceuticals Inc |
Metodo para el tratamiento de transtornos funcionales del intestino.
|
|
DE602004029982D1
(de)
*
|
2003-01-30 |
2010-12-23 |
Lek Pharmaceuticals |
Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
|
|
KR101194453B1
(ko)
*
|
2003-01-31 |
2012-10-24 |
다이이찌 산쿄 가부시키가이샤 |
동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
|
|
WO2005079752A2
(en)
*
|
2004-02-11 |
2005-09-01 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
|
US7838552B2
(en)
*
|
2004-06-04 |
2010-11-23 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
KR20070074576A
(ko)
*
|
2004-10-29 |
2007-07-12 |
코와 가부시키가이샤 |
사구체 질환 치료제
|
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
|
US20090123536A1
(en)
*
|
2005-02-21 |
2009-05-14 |
Flamel Technologies, S.A. |
Oral Pharmaceutical Form of Losartan
|
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
|
CN101247832B
(zh)
*
|
2005-06-27 |
2011-12-28 |
第一三共株式会社 |
含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂
|
|
DE102005031577A1
(de)
*
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
|
|
WO2007074406A2
(en)
|
2005-07-11 |
2007-07-05 |
Pharmena North America Inc. |
Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
|
|
TWI399223B
(zh)
*
|
2006-09-15 |
2013-06-21 |
Daiichi Sankyo Co Ltd |
奧美沙坦酯及氨氯地平之固體劑型
|
|
KR100888131B1
(ko)
*
|
2006-10-10 |
2009-03-11 |
한올제약주식회사 |
시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
|
|
WO2009084040A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Rubicon Research Private Limited |
Once a day formulation of angiotensin receptor blockers
|
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
AU2009223061B2
(en)
|
2008-03-11 |
2014-10-09 |
Depomed Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
CN102065847A
(zh)
*
|
2008-04-29 |
2011-05-18 |
韩诺生物制约株式会社 |
含有血管紧张素-ⅱ受体阻断剂的药物制剂
|
|
TW201014850A
(en)
|
2008-09-25 |
2010-04-16 |
Takeda Pharmaceutical |
Solid pharmaceutical composition
|
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
|
EP3195896A1
(en)
|
2009-05-05 |
2017-07-26 |
Board of Regents, The University of Texas System |
Novel formulations of volatile anesthetics and methods of use for reducing inflammation
|
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
EP2392318A1
(en)
|
2010-05-21 |
2011-12-07 |
Laboratorios Liconsa, S.A. |
A pharmaceutical controlled release composition of losartan
|
|
JP6245983B2
(ja)
|
2010-08-11 |
2017-12-13 |
ドレクセル ユニバーシティ |
パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
|
|
EP2648754A4
(en)
|
2010-12-07 |
2016-02-24 |
Philadelphia Health & Educatio |
METHOD OF INHIBITING CANCER METASTASES
|
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
|
US9050335B1
(en)
|
2011-05-17 |
2015-06-09 |
Mallinckrodt Llc |
Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
|
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
JP5977837B2
(ja)
|
2011-12-21 |
2016-08-24 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
Ｂ型肝炎抗ウイルス剤
|
|
BR112014027618A2
(pt)
|
2012-05-07 |
2017-06-27 |
Bayer Pharma AG |
processo para a fabricação de uma forma de dosagem farmacêutica compreendendo nifedipina e candesartan cilexetil
|
|
US9388126B2
(en)
|
2012-07-19 |
2016-07-12 |
Drexel University |
Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
|
CN107184569A
(zh)
|
2012-08-09 |
2017-09-22 |
迪纳米斯治疗公司 |
保持或改善对象健康、幸福和/或生理功能的方法
|
|
ES2828735T3
(es)
|
2013-01-07 |
2021-05-27 |
Univ Pennsylvania |
Composiciones y métodos para el tratamiento del linfoma cutáneo de células T
|
|
WO2014197744A1
(en)
|
2013-06-05 |
2014-12-11 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
ES2769893T3
(es)
|
2013-07-02 |
2020-06-29 |
Ecoplanet Env Llc |
Formulaciones de compuestos orgánicos volátiles que tienen actividad antimicrobiana
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
EP3041463A1
(en)
|
2013-09-02 |
2016-07-13 |
Sun Pharmaceutical Industries Ltd |
Pulsatile-release dosage form
|
|
EP3074049B1
(en)
|
2013-11-26 |
2020-05-06 |
Yale University |
Novel cell-penetrating compositions and methods using same
|
|
JP6449293B2
(ja)
|
2013-12-06 |
2019-01-09 |
ジェネンテック， インコーポレイテッド |
セリン／トレオニンキナーゼ阻害剤
|
|
EP3079692A4
(en)
|
2013-12-09 |
2017-10-18 |
Thomas Jefferson University |
Novel methods of treating a neurodegenerative disease in a mammal in need thereof
|
|
CA2982270C
(en)
|
2014-04-07 |
2023-01-10 |
Women & Infants Hospital Of Rhode Island |
Novel 7-dehydrocholesterol derivatives and methods using same
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN106714809A
(zh)
|
2014-08-20 |
2017-05-24 |
耶鲁大学 |
对治疗或预防肝脏疾病或障碍和促进体重减轻有用的新型组合物和方法
|
|
US10597368B2
(en)
|
2015-05-08 |
2020-03-24 |
Brown University |
Syringolin analogues and methods of making and using same
|
|
EP4414028A3
(en)
|
2015-05-19 |
2024-11-27 |
Yale University |
Compositions for treating pathological calcification conditions, and methods using same
|
|
US10829440B2
(en)
|
2015-06-12 |
2020-11-10 |
Brown University |
Antibacterial compounds and methods of making and using same
|
|
JP6731427B2
(ja)
|
2015-06-30 |
2020-07-29 |
ネウラッド リミテッドＮｅｕｒａｄ Ｌｔｄ． |
新規の呼吸制御調節化合物、およびこれを製造し、かつ使用する方法
|
|
MA42519A
(fr)
*
|
2015-07-29 |
2018-06-06 |
Takeda Gmbh |
Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique
|
|
WO2017075145A1
(en)
|
2015-10-28 |
2017-05-04 |
Yale University |
Quinoline amides and methods of using same
|
|
WO2017087936A1
(en)
|
2015-11-20 |
2017-05-26 |
Yale University |
Compositions for treating ectopic calcification disorders, and methods using same
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
US20190119364A1
(en)
|
2016-04-29 |
2019-04-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds and compositions useful for treating metabolic syndrome, and methods using same
|
|
US20210330599A1
(en)
|
2016-08-01 |
2021-10-28 |
University Of Rochester |
Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
|
|
US11390859B2
(en)
|
2016-08-05 |
2022-07-19 |
Yale University |
Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
|
|
CN109843379B
(zh)
|
2016-09-01 |
2022-12-30 |
梅比斯发现公司 |
取代脲及其制备和使用方法
|
|
JP7113009B2
(ja)
|
2016-11-07 |
2022-08-04 |
アービュタス バイオファーマ コーポレイション |
置換ピリジノン含有三環式化合物およびそれを使用する方法
|
|
EP4219486A1
(en)
|
2017-01-19 |
2023-08-02 |
Temple University of the Commonwealth System of Higher Education |
Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
|
|
EP3601216B1
(en)
|
2017-03-21 |
2023-10-25 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
|
|
JP7108018B2
(ja)
|
2017-04-17 |
2022-07-27 |
イエール ユニバーシティ |
急性肺傷害を処置または予防する化合物、組成物および方法
|
|
AU2018306726B2
(en)
|
2017-07-28 |
2023-08-03 |
Yale University |
Anticancer drugs and methods of making and using same
|
|
JP2020533298A
(ja)
|
2017-09-08 |
2020-11-19 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ |
Ｈｅｒ誘発性薬剤耐性がんの治療又は予防のための化合物、組成物及び方法
|
|
WO2019104316A1
(en)
|
2017-11-27 |
2019-05-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds, compositions, and methods for treating and/or preventing periodontal disease
|
|
US11337920B2
(en)
|
2017-12-18 |
2022-05-24 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
|
|
EP3740188A1
(en)
|
2017-12-18 |
2020-11-25 |
Tris Pharma, Inc. |
Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
WO2019126218A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
|
|
US11666546B2
(en)
|
2017-12-18 |
2023-06-06 |
Tris Pharma, Inc |
GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
WO2019125184A1
(en)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Use of biomarker in cancer therapy
|
|
US11325920B2
(en)
|
2018-01-24 |
2022-05-10 |
The Rockefeller University |
Antibacterial compounds, compositions thereof, and methods using same
|
|
KR20210095998A
(ko)
|
2018-05-25 |
2021-08-04 |
템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
항-아밀로이드 단클론성 항체를 사용하는 세균성 생물막의 박멸
|
|
MX2020012805A
(es)
|
2018-05-29 |
2021-02-15 |
Cersci Therapeutics Inc |
Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.
|
|
TWI869058B
(zh)
|
2018-07-27 |
2025-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
CN112703009B
(zh)
|
2018-08-17 |
2024-06-11 |
宾夕法尼亚大学董事会 |
治疗急性肺损伤的组合物和方法
|
|
CN112839661A
(zh)
|
2018-10-11 |
2021-05-25 |
萨尼菲特治疗有限公司 |
用于治疗异位钙化的肌醇磷酸酯类
|
|
WO2020081762A1
(en)
|
2018-10-19 |
2020-04-23 |
Temple University-Of The Commonwealth System Of Higher Education |
Tamper-resistant drug dosage forms and methods of making and use thereof
|
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
MX2021008966A
(es)
|
2019-01-30 |
2021-11-04 |
Sanifit Therapeutics S A |
Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.
|
|
US20200246316A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
|
WO2020159588A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
|
WO2020227603A1
(en)
|
2019-05-09 |
2020-11-12 |
The Feinstein Institutes For Medical Research |
Hmgb1 antagonist
|
|
EP3983391A4
(en)
|
2019-06-12 |
2023-06-28 |
The Wistar Institute |
Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
|
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
|
EP3818983A1
(en)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
|
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
|
MX2022015772A
(es)
|
2020-06-09 |
2023-05-19 |
Inozyme Pharma Inc |
Proteínas enpp1 o enpp3 solubles y sus usos.
|
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
|
EP4036097A1
(en)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds
|
|
EP4561585A1
(en)
|
2022-07-29 |
2025-06-04 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
TW202412815A
(zh)
|
2022-07-29 |
2024-04-01 |
西班牙商薩尼菲特治療公司 |
Ip5經取代化合物
|
|
IL319372A
(en)
|
2022-09-06 |
2025-05-01 |
Hadasit Med Res Service |
Combinations involving psychedelic drugs for the treatment of chronic schizophrenia and other neuropsychiatric and neurological disorders
|
|
US20250057848A1
(en)
|
2023-08-14 |
2025-02-20 |
Neurim Pharmaceuticals (1991) Ltd. |
Gal475 compositions and methods of use thereof
|
|
WO2025162971A1
(en)
|
2024-01-31 |
2025-08-07 |
Sanifit Therapeutics, S.A. |
Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
WO2025217096A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
|
|
WO2025217094A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
|
|
WO2025217379A1
(en)
|
2024-04-10 |
2025-10-16 |
University Of Rochester |
Drug treatment for macular degeneration
|